Pain management research goes beyond the obvious.
Thompson
Cheryl A
CA
D000701:Analgesics, Opioid / Q000009:adverse effects* / Q000627:therapeutic use; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D003248:Constipation / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D009271:Naltrexone / Q000031:analogs & derivatives / Q000627:therapeutic use; D009292:Narcotic Antagonists / Q000627:therapeutic use; D010146:Pain / Q000188:drug therapy*; D010880:Piperidines / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D000644:Quaternary Ammonium Compounds / Q000627:therapeutic use; D017450:Receptors, Opioid, mu / Q000037:antagonists & inhibitors; D007212:Indolizines; D011720:Pyrazoles
D000701:Analgesics, Opioid; D000893:Anti-Inflammatory Agents; D009271:Naltrexone; D009292:Narcotic Antagonists; D010880:Piperidines; D011725:Pyridines; D000644:Quaternary Ammonium Compounds; D017450:Receptors, Opioid, mu; C032257:methylnaltrexone; C419502:alvimopan; C038366:ibudilast; D007212:Indolizines; D011720:Pyrazoles